Gilead to Slice List Prices of Liver Drugs

The drugmaker intends to slash the list price of its hepatitis C treatments as it responds to competitive pricing pressures and shifts in the U.S. payment system for pharmaceuticals.

from WSJ.com: US Business https://ift.tt/2Idsq5c
via IFTTT